In-Vivo Evaluation of an In Situ Polymer Precipitation Delivery System for a Novel Natriuretic Peptide

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Lim, Soo Ghim ^a   Venkatraman, Subbu S ^a   Burnett, John C ^b   Chen, Horng H ^b  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD NP; CYCLIC GMP; NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SCREENING; DRUG URINE LEVEL; GEL; IN SITU POLYMER PRECIPITATION DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; SUSTAINED DRUG RELEASE; VASODILATATION;

EID: 84874174832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052484     Document Type: Article

References (33)

1. WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, et al (2010) Heart Disease and Stroke Statistics -2010 Update: A Report From the American Heart Association. Circulation 121: e46-215.
2. Peacock WF, Emerman CL, Young J, (2004) Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy. Journal of Cardiac Failure 10: 120-125.
3. Arora RR, Venkatesh PK, Molnar J, (2006) Short and long-term mortality with nesiritide. American Heart Journal 152: 1084-1090.
4. Shah SJ, Michaels AD, (2010) Acute Effects of Intravenous Nesiritide on Cardiac Contractility in Heart Failure. Journal of Cardiac Failure 16: 720-727.
5. Kohzu H, Nakatani S, Yokoyama H, Ohara T, Kasahara Y, et al. (2007) Limitations of Carperitide Therapy in Acute Decompensated Heart Failure Patients with Systolic Dysfunction. Journal of Cardiac Failure 13: S40-S40.
6. Lee C, Burnett J, (2007) Natriuretic peptides and therapeutic applications. Heart Failure Reviews 12: 131-142.
7. La Villa G, Mannelli M, Lazzeri C, Vecchiarino S, De Feo ML, et al. (1998) Different effects of atrial and C-type natriuretic peptide on the urinary excretion of endothelin-1 in man. Clinical Science 95: 595-602.
8. Igaki T, Itoh H, Suga SI, Hama N, Ogawa Y, et al. (1998) Effects of intravenously administered C-type natriuretic peptide in humans: Comparison with atrial natriuretic peptide. Hypertension Research 21: 7-13.
9. Horio T, Tokudome T, Maki T, Yoshihara F, Suga SI, et al. (2003) Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 144: 2279-2284.
10. Hunt P, Richards A, Espiner E, Nicholls M, Yandle T, (1994) Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 78: 1428-1435.
11. Clavell AL, Stingo AJ, Wei CM, Heublein DM, Burnett JC Jr, (1993) C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol Regul Integr Comp Physiol 264: R290-295.
12. Wei CM, Aarhus LL, Miller VM, Burnett JC Jr (1993) Action of C-type natriuretic peptide in isolated canine arteries and veins. American Journal of Physiology - Heart and Circulatory Physiology 264.
13. McKie P, Sangaralingham S, Burnett J, (2010) CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease. Current Heart Failure Reports 7: 93-99.
14. Lisy O, Burnett JC, (2003) The design, synthesis and cardiorenal actions of a new chimeric natriuretic peptide CD-NP. Journal of the American College of Cardiology 41: 312-312.
15. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr, (2008) Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP. Journal of the American College of Cardiology 52: 60-68.
16. Dunn RL, English JP, Cowsar DR, Vanderbilt DP (1990) Biodegradable in-situ forming implants and methods of producing the same. US Patent 4,938,763.
17. Packhaeuser CB, Schnieders J, Oster CG, Kissel T, (2004) In situ forming parenteral drug delivery systems: An overview. European Journal of Pharmaceutics and Biopharmaceutics 58: 445-455.
18. Graham PD, Brodbeck KJ, McHugh AJ, (1999) Phase inversion dynamics of PLGA solutions related to drug delivery. Journal of Controlled Release 58: 233-245.
19. Brodbeck KJ, DesNoyer JR, McHugh AJ, (1999) Phase inversion dynamics of PLGA solutions related to drug delivery: Part II. The role of solution thermodynamics and bath-side mass transfer. Journal of Controlled Release 62: 333-344.
20. Sartor O, (2003) Eligard: Leuprolide acetate in a novel sustained-release delivery system. Urology 61: 25-31.
21. Sartor O, (2006) Eligard® 6: A New Form of Treatment for Prostate Cancer. European Urology Supplements 5: 905-910.
22. Ravivarapu HB, Moyer KL, Dunn RL, (2000) Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. International Journal of Pharmaceutics 194: 181-191.
23. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, et al. (1999) Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. Journal of Biomedical Materials Research 45: 231-239.
24. Akesson B (1994) Nordic experts group for criteria documentation for health risks to chemicals: N-methyl-2-pyrrolidone (NMP). Arbete Och Halsa: 1-24.
25. Lee KP, Chromey NC, Culik R, Barnes JR, Schneider PW, (1987) Toxicity of N-methyl-2-pyrrolidone (NMP): Teratogenic, subchronic, and two-year inhalation studies. Fundamental and Applied Toxicology 9: 222-235.
26. Andersen F (2003) Final report on the safety assessment of triacetin. International Journal of Toxicology.
27. Evans D, Lieu H (2012) Methods of treatment with natriuretic peptides. US Patent, us 20120178689.
28. Brown RE, Jarvis KL, Hyland KJ, (1989) Protein measurement using bicinchoninic acid: elimination of interfering substances. Analytical Biochemistry 180: 136-139.
29. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, et al. (2005) C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 45: 608-616.
30. Del Ry S, (2005) Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation. Clinical Chemistry and Laboratory Medicine 43: 641-645.
31. Kim TK, Burgess DJ, (2002) Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model. J Pharm Pharmacol 54: 897-905.
32. Dickey DM, Burnett JC, Potter LR, (2008) Novel Bifunctional Natriuretic Peptides as Potential Therapeutics. Journal of Biological Chemistry 283: 35003-35009.
33. Misono KS, Grammer RT, Fukumi H, Inagami T, (1984) Rat atrial natriuretic factor: Isolation, structure and biological activities of four major peptides. Biochemical and Biophysical Research Communications 123: 444-451.